A study to investigate the efficacy, safety and tolerability of votoplam in participants with Huntin
Study Description
This study will have a variable double-blind treatment duration of up to 36 months. As part of the study design, not every participant will complete 36 months of treatment.
The study consists of 3 periods:
Screening Period: A period of up to 42-days to assess participants eligibility
Double-blind Treatment Period: This period will have variable individual treatment duration, up to 36 months. The double-blind treatment period concludes when ≥50% patients complete Month 36. The maximum treatment duration for an individual participant is 36 months.
Safety Follow-up Period: A period consisting of one safety follow-up visit, conducted on site or by phone call, for all participants not continuing treatment in the separate open-label extension study or discontinuing early. The visit/phone call will take place 30 days after End of Study (EOS)
Eligibility
INCLUSION CRITERIA
- Signed informed consent obtained before study participation.
- Ambulatory male or female, age 21 to 70 years, inclusive, on the date of signing informed consent.
- Genetically confirmed Huntington's disease (HD) with a cytosine-adenine-guanine (CAG) repeat length of at least 40. Genetic confirmation and known CAG repeat length must be obtained before screening.
- Meets ALL of the following:
a. UHDRS Independence Scale (IS) score of at least 90.
b. UHDRS Total Functional Capacity (TFC) score of 13.
c. UHDRS Total Motor Score (TMS) of 7 to 25, inclusive.
d. CAP100 score of at least 70. Calculation: CAP = Age at study entry x (CAG repeat length - 30) / 6.49.
EXCLUSION CRITERIA
- History of gene therapy, cell transplantation, or any other experimental brain surgery for treatment of HD.
- Serologic evidence of active viral hepatitis, indicated by any of the following:
a. Positive anti-HBc IgM.
b. Positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA.
c. Positive HCV antibody test confirmed by positive HCV RNA.
- Immunodeficiency disease, including a positive human immunodeficiency virus (HIV) test result.
- History or current diagnosis of ECG or cardiac abnormalities indicating a significant safety risk, including:
a. Concomitant clinically significant cardiac arrhythmias, such as sustained ventricular tachycardia.
b. Clinically significant second- or third-degree atrioventricular (AV) block without a pacemaker.
c. History of familial long QT syndrome or known family history of Torsade de Pointes.
- Women of childbearing potential who are not using highly effective contraception with a failure rate of less than 1% per year during study treatment and for 8 months after stopping study treatment.
Women of childbearing potential are defined as women physiologically capable of becoming pregnant, from menarche until menopause, unless they underwent bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral salpingectomy at least 6 weeks before study treatment. For oophorectomy alone, reproductive status must be confirmed by follow-up hormone level assessment.
- Pregnant or breastfeeding women.
OTHER PROTOCOL-DEFINED INCLUSION/EXCLUSION CRITERIA MAY APPLY.